Advances in viral-vector systemic cytokine gene therapy against cancer

被引:30
作者
Liu, Lihua [1 ,2 ]
Wang, Shijie [1 ,2 ]
Shan, Baoen [1 ,2 ]
Sang, Meixiang [1 ,2 ]
Liu, Shuang [3 ]
Wang, Guiying [1 ,2 ]
机构
[1] Hebei Med Univ, Res Ctr, Clin Hosp 4, Shijiazhuang 050011, Peoples R China
[2] Hebei Canc Inst, Shijiazhuang 050011, Peoples R China
[3] Hebei Med Univ, Dept Pathol, Clin Hosp 4, Shijiazhuang 050011, Peoples R China
关键词
Cancer; Gene therapy; Cytokine; Viral-vector; PHASE-I TRIAL; AUTOLOGOUS MELANOMA-CELLS; THYMIDINE KINASE GENE; PROSTATE-CANCER; CLINICAL-TRIAL; OVARIAN-CANCER; TUMOR-CELLS; GM-CSF; IMMUNOLOGICAL FINDINGS; METASTATIC MELANOMA;
D O I
10.1016/j.vaccine.2010.03.041
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Current strategies for cancer gene therapy consist mainly of direct inhibition of tumor cell growth and activation of systemic host defense mechanisms. Cytokine gene-transduced tumor cells have been used as vaccines in clinical trials, which have shown good safety profiles and some local responses but substantial lack of systemic efficacy. Cytokines should be directed at the level of gene selection and delivery, in order to identify the optimal cytokine and achieve efficient and durable cytokine expression at the level of improving immune stimulation. In this review, we will summarize the current achievements of cytokine gene therapy, especially viral-vector, and their applications in cancer treatment. Additionally, we will also discuss and propose future perspectives about cancer gene therapy. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3883 / 3887
页数:5
相关论文
共 61 条
  • [1] Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells
    Arienti, F
    Belli, F
    Napolitano, F
    Sulé-Suso, J
    Mazzocchi, A
    Gallino, GF
    Cattelan, A
    Sanantonio, C
    Rivoltini, L
    Melani, C
    Colombo, MP
    Cascinelli, N
    Maio, M
    Parmiani, G
    [J]. HUMAN GENE THERAPY, 1999, 10 (18) : 2907 - 2916
  • [2] An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
    Bischoff, JR
    Kim, DH
    Williams, A
    Heise, C
    Horn, S
    Muna, M
    Ng, L
    Nye, JA
    SampsonJohannes, A
    Fattaey, A
    McCormick, F
    [J]. SCIENCE, 1996, 274 (5286) : 373 - 376
  • [3] Chung TDK, 1998, CANCER GENE THER, V5, P344
  • [4] Crowther C, 2008, HUM GENE THER, V19, P1325, DOI [10.1089/hum.2008.066, 10.1089/hgt.2008.066]
  • [5] Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: A phase I trial in metastatic melanoma
    Duval, L
    Schmidt, H
    Kaltoft, K
    Fode, K
    Jensen, JJ
    Sorensen, SM
    Nishimura, MI
    von der Maase, H
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (04) : 1229 - 1236
  • [6] ABLATION OF E2A IN RECOMBINANT ADENOVIRUSES IMPROVES TRANSGENE PERSISTENCE AND DECREASES INFLAMMATORY RESPONSE IN MOUSE-LIVER
    ENGELHARDT, JF
    YE, XH
    DORANZ, B
    WILSON, JM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (13) : 6196 - 6200
  • [7] Fillat C., 2003, Current Gene Therapy, V3, P13, DOI 10.2174/1566523033347426
  • [8] Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
    Fong, Lawrence
    Kwek, Serena S.
    O'Brien, Shaun
    Kavanagh, Brian
    McNeel, Douglas G.
    Weinberg, Vivian
    Lin, Amy M.
    Rosenberg, Jonathan
    Ryan, Charles J.
    Rini, Brian I.
    Small, Eric J.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 609 - 615
  • [9] Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-γ retroviral vector in melanoma patients
    Fujii, S
    Huang, S
    Fong, TC
    Ando, D
    Burrows, F
    Jolly, DJ
    Nemunaitis, J
    Hoon, DSB
    [J]. CANCER GENE THERAPY, 2000, 7 (09) : 1220 - 1230
  • [10] Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
    Gregorc, V.
    Santoro, A.
    Bennicelli, E.
    Punt, C. J. A.
    Citterio, G.
    Timmer-Bonte, J. N. H.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    van Herpen, C. M. L.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 101 (02) : 219 - 224